NEW YORK (GenomeWeb News) – Invitrogen said today it will continue to screen kinase inhibitors for Chroma Therapeutics after the companies extended an earlier agreement.
 
Invitrogen will use its SelectScreen service at its facility in Paisley, Scotland, to screen targets, study phylogenetic diversity, and explore signaling pathways to help Chroma Therapeutics “rapidly confirm the selectivity and potency of our small-molecule drugs,” Chroma Therapeutics CSO Alan Drummond said in a statement.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.